<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01057758</url>
  </required_header>
  <id_info>
    <org_study_id>2008-002019-42</org_study_id>
    <secondary_id>2008 13</secondary_id>
    <nct_id>NCT01057758</nct_id>
  </id_info>
  <brief_title>STATIN-VAP STATIN-VAP - STATINs and Ventilator-Associated Pneumonia</brief_title>
  <official_title>Effect of the Association of a Statin to Antibiotics on the Prognosis of Patients Presenting With a Suspicion of Ventilator-associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess the efficacy and safety of oral simvastatin in patients with a
      suspicion of ventilator-associated pneumonia (VAP). The hypothesis of this study is that
      simvastatin therapy will improve mortality in patients a suspicion of VAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When a patient will present a suspicion of VAP (Clinical Pulmonary Infection Score modified ≥
      5), Simvastatin or placebo will be administered with antibiotics. Quantitative cultures will
      be performed for microbiological confirmation of VAP. Simvastatin or placebo will be
      administered through an enteral feeding tube or administered orally when patients are able to
      safely take oral medications. The type and placement of the enteral feeding tube
      (nasogastric, nasoenteric, PEG, orogastric, oroenteric, etc.) and the ability to safely take
      oral medications will be determined by the patient's primary team. Study drug will be blinded
      with an identical appearing placebo.

      Sequential Organ Failure Assessment score (SOFA), and various blood factors will be measured
      during treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    stopped for futility
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary efficacy measure is hospital mortality to day 28.</measure>
    <time_frame>28 days after randomization</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of the patients will be randomized to the placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the subjects will receive the active drug, Simvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIMVASTATIN</intervention_name>
    <description>Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Duration of mechanical ventilation &gt; 48 h

          -  First episode of suspicion of VAP with a Clinical Pulmonary Infection Score modified ≥
             5

          -  BAL, plugged telescopic catheter and/or tracheal aspirates quantitative cultures
             performed prior administration of antibiotics

          -  Informed consent

        Exclusion Criteria:

          -  Statin treatment received under mechanical ventilation

          -  Age less than 18 years

          -  Pregnancy

          -  Unable to receive or unlikely to absorb enteral study drug

          -  Patient, surrogate, or physician not committed to full support ).

          -  Moribund patient with a SAPS II score &gt; 75

          -  Simvastatin specific exclusions Allergy or intolerance to statins Physician insistence
             for the use or avoidance of statins during the current hospitalization CK , ALT or AST
             &gt; 5 times the upper limit of normal Receiving cyclosporine, gemfibrozil, lopinavir,
             ritonavir itraconazole, kétoconazole, érythromycine, clarithromycine, télithromycine,
             néfazodone, verapamil, diltiazem

          -  Severe chronic liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURENT PAPAZIAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2010</study_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Suspicion of ventilator-associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

